Welcome to Paid Research Studies




  • Conditions:   Bronchiolitis Obliterans;   Constructive Bronchiolitis;   Graft Versus Host Disease;   Bronchiolitis, Exudative;   Bronchiolitis, Proliferative
    Intervention:   Drug: Cyclosporine Inhalation Solution (CIS)
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Nephrotic Syndrome;   Proteinuria;   Autoimmune Disease;   Glomerular Disease;   Membranous Glomerulonephritis
    Interventions:   Drug: Rituximab Infusion;   Drug: Oral Cyclosporine
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   CD30-Positive Neoplastic Cells Present
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Verapamil
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: hATG;   Drug: Cyclosporine;   Drug: Methylprednisone;   Drug: Pegfilgrastim;   Drug: Filgrastim
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Mycoses;   Sezary Syndrome;   Lymphoma, T-Cell, Cutaneous;   Bone Marrow Transplant Failure;   Lymphoma, Non-Hodgkin;   Cutaneous T-cell Lymphoma
    Interventions:   Drug: anti-thymocyte globulin;   Drug: cyclosporine;   Radiation: Lymphoid radiation
    Sponsor:   Stanford University
    Recruiting

  • Condition:   Colitis, Ulcerative
    Intervention:   Drug: ST-0529
    Sponsors:   Sublimity Therapeutics Holdco Limited;   Dr. Falk Pharma GmbH
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Therapeutic Allogeneic Lymphocytes;   Radiation: Total Nodal Irradiation
    Sponsors:   Robert Lowsky;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
    Interventions:   Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   University of California, Davis;   Spectrum Pharmaceuticals, Inc
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   High Risk Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non Malignant Diseases;   Immunodeficiencies;   Hemoglobinopathies
    Interventions:   Drug: RIC: Distal Campath;   Drug: RIC:Intermediate Campath;   Drug: RIC: Mini Busulfan
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Post-Transplant Lymphoproliferative Disorder;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Radiation: Indium In-111 Ibritumomab Tiuxetan;   Drug: Mycophenolate Mofetil;   Other: Pharmacological Study;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Diffuse Large B-Cell Lymphoma;   Adult Myelodysplastic Syndrome;   Adult Non-Hodgkin Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Diffuse Large B-Cell Lymphoma;   Childhood Myelodysplastic Syndrome;   Childhood Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hematopoietic and Lymphoid Cell Neoplasm;   Mantle Cell Lymphoma;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Bronchiolitis Obliterans
    Intervention:   Drug: Liposomal Cyclosporine A
    Sponsor:   Breath Therapeutics Inc.
    Recruiting

  • Condition:   Bronchiolitis Obliterans
    Intervention:   Drug: Liposomal Cyclosporine A
    Sponsor:   Breath Therapeutics Inc.
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Myelodysplastic Syndrome;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Lupus Nephritis
    Interventions:   Drug: Voclosporin;   Drug: Placebo Oral Capsule
    Sponsor:   Aurinia Pharmaceuticals Inc.
    Recruiting

  • Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
    Interventions:   Biological: Thymus Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
    Sponsors:   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Enzyvant Therapeutics GmbH
    Available

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Lymphocytic Leukemia;   Loss of Chromosome 17p;   Myelodysplastic/Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Aggressive Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Atorvastatin Calcium;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Dry Eye Disease
    Intervention:   Drug: Corticotropin 80Unit/Ml Repository Injection
    Sponsors:   Toyos Clinic;   Mallinckrodt
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
    Interventions:   Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
    Sponsors:   Boston Children’s Hospital;   Dana-Farber Cancer Institute;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Los Angeles;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   Baylor College of Medicine;   Children's Hospital of Philadelphia;   Memorial Sloan Kettering Cancer Center;   University of Wisconsin, Madison;   Karolinska University Hospital
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aggressive Non-Hodgkin Lymphoma;   Beta-2-Microglobulin Greater Than 3 g/mL;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   Chromosome 13 Abnormality;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Uveitis
    Interventions:   Biological: Adalimumab (ADA);   Drug: Conventional immunosuppression (CON)
    Sponsor:   JHSPH Center for Clinical Trials
    Not yet recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: cyclosporine;   Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;   Drug: horse anti-thymocyte globulin (ATG);   Drug: rabbit anti-thymocyte globulin (ATG);   Drug: methotrexate;   Drug: fludarabine;   Drug: cyclophosphamide;   Radiation: low-dose total body irradiation (TBI);   Procedure: Immunosuppressive Therapy (IST)
    Sponsor:   Michael Pulsipher, MD
    Recruiting

  • Condition:   Cytomegalovirus Infections
    Intervention:   Drug: Letermovir
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Non-Malignant
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
    Recruiting

  • Conditions:   Hematologic Diseases;   Acute Myeloid Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia - Chronic Phase;   Chronic Myelogenous Leukemia, Accelerated Phase;   Chronic Myelogenous Leukemia, Blastic Phase;   Myelodysplastic Syndromes;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma;   Non Hodgkin Lymphoma;   Graft Vs Host Disease;   Graft-versus-host-disease
    Interventions:   Drug: Vorinostat;   Procedure: Blood and Marrow Transplant (BMT);   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Michigan Rogel Cancer Center
    Not yet recruiting

  • Condition:   Focal Segmental Glomerulosclerosis
    Intervention:   Drug: Voclosporin
    Sponsor:   Aurinia Pharmaceuticals Inc.
    Recruiting

  • Condition:   CMV Disease
    Interventions:   Drug: Letermovir;   Drug: Valganciclovir;   Drug: Acyclovir (ACV);   Drug: Placebo to ACV;   Drug: Placebo to LET;   Drug: Placebo to VGCV
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   HIV Infections;   Kidney Diseases
    Interventions:   Drug: Maraviroc;   Drug: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Itacitinib;   Drug: Calcineurin inhibitor
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Aplastic Anemia
    Interventions:   Drug: Eltrombopag;   Drug: hATG;   Drug: CsA
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   Rafic Farah, MD
    Recruiting

  • Condition:   Heart Transplant
    Interventions:   Biological: tocilizumab;   Biological: Placebo;   Drug: Standard of Care Triple IS
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Psoriasis;   Arthritis, Psoriatic
    Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting